0
     

Report Added
Report already added
Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 74, 36, 3, 98, 36 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 1, 7 and 4 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Atopic Dermatitis (Atopic Eczema) - Overview
Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Drug Profiles
Atopic Dermatitis (Atopic Eczema) - Dormant Projects
Atopic Dermatitis (Atopic Eczema) - Discontinued Products
Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Adare Pharma Solutions, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Akeso Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Alexion Pharmaceuticals Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Allakos Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergy Therapeutics Plc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amicogen Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amtixbio Co Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amytrx Therapeutics Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Annji Pharmaceutical Co Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Biotherapeutics Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Attillaps Holdings Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Avixgen Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Azitra Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Beijing Puqi Pharmaceutical Technology Co Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by BenevolentAI Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by BioMarck Pharmaceuticals Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by BioMe Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Biomimetix JV LLC, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by BiomX Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Biosion Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Bioversys AG, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Biozeus Pharmaceutical SA, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Blueberry Therapeutics Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Boehringer Ingelheim International GmbH, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Boryung ViGenCell Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Botanix Pharmaceuticals Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Brandenburg Antiinfektiva GmbH, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Brexogen Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Brickell Biotech Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Bristol-Myers Squibb Co, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Cellivery Therapeutics Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by CELLnLIFE Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Clayton Biotechnologies Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Clevexel Pharma SA, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by CSA Biotechnologies LLC, 2022
Atopic Dermatitis (Atopic Eczema) - Pipeline by Cugene Inc, 2022
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, 2022
Atopic Dermatitis (Atopic Eczema) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F

India Blood Bags Market, By Product (Single Blood Bag, Triple Blood Bag, Double Blood Bag, Quadruple Blood Bag, Penta Blood Bag), By Type (Collection Bag v/s Transfer Bag), By Volume (450ml, 350ml, 150ml, 100ml, 250ml, Others), By Material (PVC, PET, Others), By End-User (Hospitals and Clinics, Blood Banks, Ambulatory Surgical Centers, Others), By Region, Competition, Forecast & Opportunities, 2018-2028F

India Blood Bags Market, By Product (Single Blood Bag, Triple Blood Bag, Double Blood Bag, Quadruple Blood Bag, Penta Blood Bag), By Type (Collection Bag v/s Transfer Bag), By Volume (450ml, 350ml, 150ml, 100ml, 250ml, Others), By Material (PVC, PET, Others), By End-User (Hospitals and Clinics, Blood Banks, Ambulatory Surgical Centers, Others), By Region, Competition, Forecast & Opportunities, 2018-2028F

Global Xenotransplantation Market By Animal Type (Pig, Rabbit, Baboon, Others), By Xeno Products (Organs, Tissues, Cells), By Organs (Kidney, Liver, Heart, Cornea, Others), By End Users (Transplants Center, Hospitals, Others), By Region, Competition Forecast & Opportunities, 2027

Global Xenotransplantation Market By Animal Type (Pig, Rabbit, Baboon, Others), By Xeno Products (Organs, Tissues, Cells), By Organs (Kidney, Liver, Heart, Cornea, Others), By End Users (Transplants Center, Hospitals, Others), By Region, Competition Forecast & Opportunities, 2027

Global Minimally Invasive Biopsy Techniques Market By Product Offered (Tests, Kits & Consumables, Instruments), By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy etc.}), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA, CTECs, circRNA etc.}), By Application (Clinical v/s Therapeutic), By End User (Hospitals & Clinics, Ambulatory Care Center, Academic & Research Institutions), By Region, Competition Forecast & Opportunities, 2027

Global Minimally Invasive Biopsy Techniques Market By Product Offered (Tests, Kits & Consumables, Instruments), By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy etc.}), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA, CTECs, circRNA etc.}), By Application (Clinical v/s Therapeutic), By End User (Hospitals & Clinics, Ambulatory Care Center, Academic & Research Institutions), By Region, Competition Forecast & Opportunities, 2027

Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027

Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027